Rhythm Pharmaceuticals (RYTM) Total Non-Current Liabilities (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has 6 years of Total Non-Current Liabilities data on file, last reported at $210.2 million in Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities fell 7.71% year-over-year to $210.2 million in Q4 2025; TTM through Dec 2025 was $210.2 million, a 7.71% decrease from a year earlier, with the FY2025 full-year figure at $210.2 million, down 7.71% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $210.2 million, down from $227.7 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for RYTM reached as high as $227.7 million in Q4 2024 and fell as low as $80.5 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $149.2 million across 4 years, with a median of $155.5 million in 2023.
• Across the five-year window, Total Non-Current Liabilities soared 57.03% in 2023 and slipped 7.71% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $116.9 million in 2022, then surged by 38.46% to $161.8 million in 2023, then surged by 40.71% to $227.7 million in 2024, then slipped by 7.71% to $210.2 million in 2025.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $210.2 million in Q4 2025, $227.7 million in Q4 2024, and $166.8 million in Q2 2024.